# Nuclide record beta-psma-then-alpha-psma-rescue (pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pairings/beta-psma-then-alpha-psma-rescue/>
  a schema:MedicalTherapy ;
  nuclide:kind "pairing" ;
  schema:identifier "beta-psma-then-alpha-psma-rescue" ;
  schema:name "177Lu-PSMA-617 then 225Ac-PSMA rescue therapy"@en ;
  schema:description "When the standard radioactive prostate cancer treatment (177Lu-PSMA) stops working, some clinics switch to a more powerful alpha-particle version (225Ac-PSMA) as a rescue option. It can bring PSA down in about half of patients, but people who have already failed the beta treatment tend to respond less well and for a shorter time than those who have never had it."@en ;
  schema:url <https://nuclide.cc/pairings/beta-psma-then-alpha-psma-rescue/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://jnm.snmjournals.org/content/64/10/1574>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8852230/>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11816130/> ;
  nuclide:tag "prostate cancer", "alpha therapy", "salvage therapy" ;
  nuclide:related <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/people/clemens-kratochwil/>, <https://nuclide.cc/people/uwe-haberkorn/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:pairs <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/ac225-psma/> .